Sloan-Kettering Institute Programs
- Cancer Biology & Genetics
- Cell Biology
- Computational Biology
- Developmental Biology
- Immunology
- Molecular Biology
- Molecular Pharmacology & Chemistry
- Structural Biology
Clinical Research
Collaborative Research Centers
- Brain Tumor Center
- Center for Cell Engineering
- Center for Health Policy & Outcomes
- Center for Stem Cell Biology
- Center for Comparative Medicine & Pathology
- Experimental Therapeutics Center
- Geoffrey Beene Cancer Research Center
- Lucille Castori Center for Microbes, Inflammation & Cancer
- Ludwig Center for Cancer Immunotherapy
- Metastasis Research Center
- Nanotechnology Center
Dr. Seshan will lead the discussion of the following two papers on two-stage design:
Gordana Jovica and John Whitehead. An exact method for analysis following a two-stage phase II cancer clinical trial. Statist. Med. 2010; 29:3118—3125. [PubMed Abstract]
Tatsuki Koyama and Heidi Chen. Proper inference from Simon’s two-stage designs. Statist. Med. 2008; 27:3145-3154. [PubMed Abstract]
Event Information
Date & Time(s)
Wednesday, February 23, 2011, 4:00 PM
Speaker(s)
Venkatraman Seshan
Assistant Attending Biostatistician
Epidemiology and Biostatistics
Memorial Sloan-Kettering Cancer Center
Contact Information
Address
307 East 63rd Street, 3rd Floor Conference Room
- Epidemiology & Biostatistics
- Directory
- Administrative Resources
- Biostatistics
- Members
- Seminars
- A Unified Competing Risks Cure Rate Model with Application to Cancer Survival Data
- An Expanded Study of Inpatient Re-admission Patterns at Memorial Sloan-Kettering
- Bayesian Models for High-Dimensional Categorical and Mixed Domain Data
- Challenges in the Analysis of Clinical Genomics Studies
- Challenges in the Analysis of Clinical Genomics Studies
- Choosing a Link Function for Additivity in the Analysis of Binary Traits
- Data Analysis Journal Discussion
- Discussing of “Correcting gene expression data when neither the unwanted variation nor the factor of interest are observed”
- Discussion of "Dynamic Prediction by Landmarking in Event History Analysis"
- Discussion of "Identifying Cancer Driver Genes in Tumor Genome Sequencing Studies."
- Discussion of A Partitioning Deletion/Substitution/Addition Algorithm for Creating Survival Risk Groups
- Discussion of Clustering For Multivariate Continuous and Discreet Longitudinal Data
- Discussion of Comparison of Continuous versus Categorical Tumor Measurement -Based Metrics to Predict Overall Survival in Cancer Treatment Trials
- Discussion of Improving the Flexibility and Efficiency of Phase II Designs for Oncology Trials
- Discussion of Predicting False Discovery Proportion Under Dependence
- Discussion on "CNAseg--a novel framework for identification of copy number changes in cancer from second-generation sequencing data"
- Discussion on "Genome-wide strategies for detecting multiple loci that influence complex diseases"
- Discussion on Computational Bottlenecks in using R.
- Discussion on various available methods for analyzing ChIP-seq data
- Estimating False Discovery Rates with Unknown Dependence
- Estimation of Cellular and Genetic Diversity
- Estimation of Empirical Null Using a Mixture of Normals and its use in Local False Discovery Rate
- From Local Ancestry to Rare Variant Analysis: Some Current Issues in Genetic Association Studies
- Genomic Data Analysis Journal Club
- Identifying Clinical and Statistical Improvement in Consolidation Single-arm Phase II Trials: the Ovarian Cancer Paradigm.
- Journal Discussion
- Journal Discussion Led by Glenn Heller
- Journal Discussion Led by Irina Ostrovnaya
- Journal discussion led by Jaya Satagopan
- Journal Discussion Led by Li-Xuan Qin
- Journal Discussion led by Marinela Capanu
- Journal Discussion Led by Sujata Patil
- Journal Discussion Led by Venkatraman Seshan
- Latent Regression Graded Response Modeling for Linking SNPs with Chemobrain
- Lessons from Studying Risk Stratification in Screening for Cervical Cancer and Lung Cancer
- Likelihood Methods vs Frequentist Cumulative Meta Analysis: A case study in Ongoing Drug Safety Surveillance of Rosiglitazone and Rofecoxib.
- Multi-Way Block Models
- Multiple Testing in a Two-Stage Adaptive Design with Combination Tests Controlling FDR
- Next-generation Genetic Association Studies: Challenges and Opportunities
- Nonparametric Estimation of Group-Specific Survival Functions from Case-Cohort Data
- Novel Algorithm for Stratifying Patients into Survival Risk Groups Using Mutation Data at Selected Genes
- Novel Pattern Discovery and Driver Gene Identification in Integrated Cancer Genomic Data
- Phase I Trials with Dose Expansions
- Random Walks on Graphs
- Re-visiting Re-admissions
- Risk Heterogeneity, Etiologic Heterogeneity and Incremental Explained Variation
- Risk Reclassification Measures for Comparing Prediction Models
- Safety Monitoring and Evaluation in Late Phase Clinical Drug Development
- Selection of Predictive Variables for Optimal Treatment Decision
- Semi-parametric Analysis of Binary Outcomes in Longitudinal Studies with Outcome-dependent Observation Times
- Seminar by Camelia Sima
- Seminar by Cami Sima
- Seminar by Daniel Schaid
- Seminar by Glenn Heller
- Seminar by Jack Kalbfleisch
- Seminar by Jaya Satagopan
- Seminar by Katherine Panageas
- Seminar by Marinela Capanu
- Seminar by Mengling Liu
- Seminar by Mithat Gönen
- Seminar by Nicholas Jewell
- Seminar by Richard J. Chappell
- Seminar by Ronglai Shen
- Seminar by Sean Devlin
- Seminar by Sujata Patil
- Seminar by Venkatraman Seshan
- Seminar by Zhigang Zhang
- Seminar by Zhigang Zhang
- Seminar by Zhigang Zhang
- Statistical Analysis of Cinical Trials Comparing Similar Treatments: Fisher or Toyota?
- Statistical Issues and Methods for a Long-Term Prevention Trial in HIV/AIDS
- Statistical Issues in Somatic Mutation Studies of Cancer
- Statistical Methods for Next-Generation Sequencing Data
- Treatment Effects in the Presence of Treatment Interruption
- Two Stage Phase I Designs: Benefits and Pitfalls
- Using the Optimal Receiver Operating Characteristic Curve to form Predictive Genetic Tests
- Why can’t medical prediction be more like Netflix? Towards Dynamic Prediction Models in Medicine
- Jobs
- Software
- Computing Resource
- Epidemiology
- Health Outcomes
- Seminars
- Software
- Publications
- Newsletter
- Jobs
Inside MSKCC
|
©2013 Memorial Sloan-Kettering Cancer Center